Slate Medicines’ antibody drug is designed to block PACAP, a protein associated with migraines. The Phase 1-ready asset was licensed from China-based DartsBio Pharmaceuticals.
The post Headache Startup Slate Medicines Lands $130M to Bring Novel Migraine Drug Into the Clinic appeared first on MedCity News.
CSO Executive Sessions ASEAN: From Compliance to Cyber Resilience-Securing Patient Trust in Southeast Asia’s Hospitals – csoonline.com
CSO Executive Sessions ASEAN: From Compliance to Cyber Resilience-Securing Patient Trust in Southeast Asia’s Hospitals csoonline.com
